Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

326.73 USD -2.44 (-0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biogen, Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021
From ACN Newswire
Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at 2021... 
From PR Newswire
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
From GlobeNewswire News Releases
Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021
From ACN Newswire
Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
- Phase 1b study of BIIB080/IONIS-MAPT Rx met primary objective of safety and tolerability 
From PR Newswire
Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
From GlobeNewswire News Releases
Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference
From GlobeNewswire News Releases
An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.
From GlobeNewswire News Releases
Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications
Mirimus, Inc., a pioneer in RNAi therapeutic design and CRISPR/Cas9 gene editing technology implementation, today announced a strategic collaboration with Biogen Inc. (NASDAQ: BIIB) focused on the... 
From PR Newswire
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021
From ACN Newswire
Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
From GlobeNewswire News Releases
Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease
From GlobeNewswire News Releases
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia 
From GlobeNewswire News Releases
MarketBeat Ranks 10 Most Upgraded Stocks by Wall Street Analysts in May 2021
The financial media company lists the most upgraded stocks on its site 
From PR Newswire
Enel X Collaborates With Biogen To Electrify Take-home Vehicle Fleet In North America
- Enel X is supporting Biogen in its goal to achieve fleet electrification of over 1,000 vehicles in North America by 2025 
From PR Newswire
Enel X Collaborates With Biogen to Electrify Take-Home Vehicle Fleet in North America
Tags electric vehicles Green Infrastructure Healthy Climate Healthy Lives
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™
From GlobeNewswire News Releases
Thinking about trading options or stock in MGM Resorts, Snap, Square, Trade Desk, or Biogen?
InvestorsObserver issues critical PriceWatch Alerts for MGM, SNAP, SQ, TTD, and BIIB. 
From PR Newswire
Alzheimer’s Treatment Market Is Anticipated To Reach $2 Billion By The End Of 2027
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Alzheimer's Treatment Market Is Anticipated To Reach $2 Billion By The End Of 2027
FinancialNewsMedia.com News Commentary 
From PR Newswire
Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced that... 
From PR Newswire
Kenan Fellows Program and Biogen Foundation Collaborate to Advance Workforce Education
Tags Grants Philanthropy & Cause Initiatives Biogen Foundation
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Thinking about trading options or stock in Prothena Corp, CureVac, Centene Corp, AMC, or Biogen?
InvestorsObserver issues critical PriceWatch Alerts for PRTA, CVAC, CNC, AMC, and BIIB. 
From PR Newswire
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
From GlobeNewswire News Releases
Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
From GlobeNewswire News Releases
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the WATERFALL Study in patients with MDD met its primary endpoint with zuranolone (SAGE-217/BIIB125) 50 mg... 
From Business Wire News Releases
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
From GlobeNewswire News Releases
Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
From GlobeNewswire News Releases
Biogen Announces Investor Day on September 21, 2021
From GlobeNewswire News Releases
New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.